

SCOPE: ALS, CCT	
MEDICATION:	FENTANYL (Sublimaze)
INTERVENTION:	<p><u>Classification:</u> Opioid analgesic, Narcotic: Schedule II controlled substance</p> <p><u>Actions:</u> Potent synthetic opioid analgesic with rapid onset and short duration; more potent, but less emetic and vasodilatory effects than Morphine</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Known hypersensitivity • Myasthenia Gravis • Monoamine Oxidase Inhibitor (MAOI) use <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Brady dysrhythmias • Respiratory depression • Risk of chest wall rigidity with rapid IV infusion • Exacerbate hypotension in the patient with hypovolemic shock • Renal or hepatic impairment <p><u>Dosage:</u></p> <p>I. <u>Pain & Anxiolysis:</u></p> <p style="padding-left: 20px;">a. Adult & Pediatric:</p> <p style="padding-left: 40px;">i. IV/IO/IM: Up to 1 mcg/kg</p> <p style="padding-left: 60px;">1. Repeat every 5 min PRN</p> <p><u>Onset of Action:</u> IV/IO: 1 minute, IM: 7-15 minutes</p> <p><u>Duration:</u> 30 minutes - 2 hours</p> <p><u>Adverse Effects:</u> Sedation, dizziness, euphoria, diaphoresis, nausea, vomiting, seizures, hypotension, bradycardia, laryngospasm, respiratory depression, chest wall rigidity, cardiac arrest</p> <p><u>Special Considerations:</u></p> <p>I. Preferred analgesic for the Obstetric population</p>

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 1